| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $11,691,573 | 22 | 100 |
| OLUKOTUN ADEOYE Y | director | 0 | $0 | 2 | $77,139 | $-77,139 |
| GIVEN DOUGLAS B | director | 0 | $0 | 2 | $121,556 | $-121,556 |
| Waddill William D. | director | 0 | $0 | 2 | $164,665 | $-164,665 |
| Vakiener Victoria | director | 0 | $0 | 1 | $197,059 | $-197,059 |
| Oliver Tracie | Chief Commercial Officer | 0 | $0 | 1 | $237,480 | $-237,480 |
| Hamilton James C | Chief Discovery/Trans Medicine | 0 | $0 | 1 | $648,824 | $-648,824 |
| O'Brien Patrick | COO and General Counsel | 0 | $0 | 2 | $736,059 | $-736,059 |
| Myszkowski Kenneth Allen | Chief Financial Officer | 0 | $0 | 2 | $893,095 | $-893,095 |
| Anzalone Christopher Richard | Chief Executive Officer | 0 | $0 | 9 | $8.62M | $-8.62M |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $0 and sold $11.69M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $64,197 and sold $20.68M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
| 2025-04-11 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 50,800 0.0415% | $11.49 | $583,692 | +14.57% | |
| 2025-04-10 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 50,000 0.0386% | $10.87 | $543,500 | +21.06% | |
| 2025-04-09 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 40,322 0.0289% | $10.07 | $406,145 | +13.67% | |
| 2025-03-13 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 51,425 0.0374% | $15.07 | $774,975 | -9.99% | |
| 2025-03-04 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 133,333 0.104% | $17.02 | $2.27M | -19.29% | |
| 2025-03-03 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 166,667 0.1344% | $18.03 | $3.01M | -21.96% | |
| 2025-01-23 | Sale | OLUKOTUN ADEOYE Y | director | 959 0.0007% | $21.00 | $20,139 | -29.82% | |
| 2025-01-07 | Sale | O'Brien Patrick | COO and General Counsel | 8,000 0.0065% | $19.69 | $157,520 | -21.20% | |
| 2025-01-07 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 18,000 0.0146% | $19.69 | $354,500 | -21.20% | |
| 2025-01-06 | Sale | O'Brien Patrick | COO and General Counsel | 29,184 0.0236% | $19.82 | $578,539 | -20.28% | |
| 2025-01-06 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 27,167 0.022% | $19.83 | $538,595 | -20.28% | |
| 2025-01-06 | Sale | Hamilton James C | Chief Discovery/Trans Medicine | 32,729 0.0265% | $19.82 | $648,824 | -20.28% | |
| 2025-01-02 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 11,520 0.009% | $19.05 | $219,456 | -20.64% | |
| 2024-12-27 | Sale | OLUKOTUN ADEOYE Y | director | 2,850 0.0024% | $20.00 | $57,000 | -16.90% | |
| 2024-12-23 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 12,563 0.0099% | $19.59 | $246,109 | -19.57% | |
| 2024-12-18 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 26,712 0.0226% | $21.24 | $567,486 | -16.65% | |
| 2024-12-17 | Sale | GIVEN DOUGLAS B | director | 547 0.0004% | $22.04 | $12,056 | -23.48% | |
| 2024-12-17 | Sale | Waddill William D. | director | 3,747 0.003% | $22.04 | $82,584 | -23.48% | |
| 2024-12-16 | Sale | GIVEN DOUGLAS B | director | 5,000 0.004% | $21.90 | $109,500 | -23.51% | |
| 2024-12-16 | Sale | Waddill William D. | director | 3,748 0.003% | $21.90 | $82,081 | -23.51% |
| Anzalone Christopher Richard | Chief Executive Officer | 3921255 2.8394% | $63.88M | 4 | 44 | <0.0001% |
| O'Brien Patrick | COO and General Counsel | 527201 0.3818% | $8.59M | 0 | 13 | |
| Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.3298% | $7.42M | 1 | 29 | <0.0001% |
| Hamilton James C | Chief Discovery/Trans Medicine | 272122 0.197% | $4.43M | 0 | 13 | |
| Oliver Tracie | Chief Commercial Officer | 127107 0.092% | $2.07M | 0 | 3 | |
| GIVEN DOUGLAS B | director | 124167 0.0899% | $2.02M | 1 | 21 | <0.0001% |
| Waddill William D. | director | 40378 0.0292% | $657,757.62 | 0 | 9 | |
| OLUKOTUN ADEOYE Y | director | 35781 0.0259% | $582,872.49 | 0 | 5 | |
| Vakiener Victoria | director | 21211 0.0154% | $345,527.19 | 0 | 4 | |
| GIVEN BRUCE D | Chief Operating Officer | 850730 0.616% | $13.86M | 0 | 19 | |
| Li Zhen | Snr. VP, Chem and Non-Clin Dev | 201700 0.1461% | $3.29M | 0 | 1 | |
| San Martin Javier | Chief Medical Officer | 198497 0.1437% | $3.23M | 0 | 5 | |
| KNOTT DAVID M | 10 percent owner | 166778 0.1208% | $2.72M | 1 | 3 | <0.0001% |
| Leone Peter Brian | VP, Strategic Bus. Initiatives | 130000 0.0941% | $2.12M | 0 | 1 | |
| Hassard James | Chief Commercial Officer | 105750 0.0766% | $1.72M | 0 | 2 | |
| PERRY MICHAEL S | director | 85500 0.0619% | $1.39M | 0 | 5 | |
| Ferrari Mauro | director | 60778 0.044% | $990,073.62 | 2 | 4 | +71% |
| Lu Hongbo | director | 33680 0.0244% | $548,647.20 | 3 | 0 | <0.0001% |
| FRYKMAN EDWARD W | director | 23852 0.0173% | $388,549.08 | 0 | 1 | |
| McKenney Charles | director | 17220 0.0125% | $280,513.80 | 1 | 16 | |
| De Backer Marianne | director | 17000 0.0123% | $276,930.00 | 9 | 2 | +50.28% |
| Kingsley Joseph Theodore III | Interim President & CFO | 12000 0.0087% | $195,480.00 | 2 | 0 | +27.7% |
| Ching Marshall Robert | 10 percent owner | 0 0% | $0 | 0 | 6 | |
| Lewis David L. | Chief Scientific Officer | 0 0% | $0 | 0 | 3 | |
| Bradshaw Curt | Chief Scientific Officer | 0 0% | $0 | 0 | 2 |
$193,151,375 | 134 | 8.18% | $2.03B | |
$20,297,544 | 73 | 103.06% | $2.16B | |
$1,376,668 | 53 | 18.46% | $2.19B | |
$224,368,761 | 42 | 28.26% | $2.25B | |
$140,165,669 | 33 | 85.24% | $2.55B | |
$5,066,938 | 27 | 26.38% | $2.41B | |
Arrowhead Pharmaceuticals, Inc. (ARWR) | $1,801,511 | 23 | 18.58% | $2.25B |
$174,105,409 | 15 | 10.88% | $2.33B | |
$91,269,919 | 12 | 12.86% | $2.94B | |
$75,296,816 | 12 | 37.23% | $2.05B | |
$35,908,794 | 10 | 126.31% | $2.89B | |
$1,248,715 | 10 | 5.66% | $2.26B | |
$117,959,652 | 9 | -12.47% | $2.56B | |
$55,713,031 | 8 | -0.36% | $2.56B | |
$25,073,947 | 7 | -5.99% | $2.05B | |
$276,224 | 2 | -7.04% | $2.17B | |
$9,900,000 | 1 | -7.19% | $2.08B | |
$7,600,000 | 1 | -4.05% | $2.02B | |
$49,999,992 | 1 | 50.02% | $2.4B |
| Increased Positions | 134 | +42.01% | 14M | +14.44% |
| Decreased Positions | 133 | -41.69% | 11M | -10.78% |
| New Positions | 43 | New | 2M | New |
| Sold Out Positions | 52 | Sold Out | 2M | Sold Out |
| Total Postitions | 320 | +0.31% | 103M | +3.66% |
| Blackrock, Inc. | $287,335.00 | 14.55% | 19.93M | +4M | +23.17% | 2025-03-31 |
| Vanguard Group Inc | $175,697.00 | 8.89% | 12.18M | -44,766 | -0.37% | 2024-12-31 |
| Avoro Capital Advisors Llc | $160,222.00 | 8.11% | 11.11M | +2M | +25% | 2024-12-31 |
| State Street Corp | $86,754.00 | 4.39% | 6.02M | -338,104 | -5.32% | 2024-12-31 |
| Slate Path Capital Lp | $75,445.00 | 3.82% | 5.23M | +347,000 | +7.1% | 2024-12-31 |
| Fmr Llc | $73,558.00 | 3.72% | 5.1M | -966,486 | -15.93% | 2024-12-31 |
| Geode Capital Management, Llc | $42,610.00 | 2.16% | 2.95M | -9,172 | -0.31% | 2024-12-31 |
| Siren, L.L.C. | $41,842.00 | 2.12% | 2.9M | +442,903 | +18.01% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $36,155.00 | 1.83% | 2.51M | -1M | -29.86% | 2024-12-31 |
| Norges Bank | $29,624.00 | 1.5% | 2.05M | +469,044 | +29.59% | 2024-12-31 |